Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

1033 - Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Soft Tissue Sarcomas

Presenters

Vasilii Ostafiichuk

Citation

Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283

Authors

V. Ostafiichuk1, S.I. Korovin2, M.N. Kukushkina2

Author affiliations

  • 1 Skin Tumors And Soft Tissue Tumors, National Cancer Institute, 03191 - kiev/UA
  • 2 Skin Tumors And Soft Tissue Tumors, National Cancer Institute, 03022 - Kiev/UA

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1033

Background

Soft tissue sarcomas are a rare subgroup in adults and children with oncological diseases. Since the 1970s, after the introduction of doxorubicin as a chemotherapeutic agent for the treatment of soft tissue sarcoma, the treatment of metastatic and primary localized sarcoma has remained weak, although several new therapeutic agents have been identified in this time. Participating in clinical trials can help solve this problem in general and particularly in countries with a low level of access to innovative medicines. We performed qualitative and quantitative comparative analysis of clinical trials for soft tissue sarcoma patients in Western and Eastern Europe.

Methods

Based on data from https://clinicaltrials.gov/ we searched for clinical trials that have been performed in 2009-2019 in 30 European countries (10 in Western and 20 in Eastern countries). Clinical trials by phases, type of therapy, soft tissue sarcoma type, stage of disease and status were studied.

Results

The vast majority of soft tissue sarcoma trials have been performed in Western Europe (401/467) and of those 212/52.9% of were phase II; average number of trials per country was 40, ranging from 30 (Switzerland) to 92 (France). In Eastern Europe the average number of trials per country was 3 with a maximum of 23 (Poland); 45.5% of trials were phase III. Clinical trials in adults (> 18 years) in Eastern Europe and Western Europe (78.8% vs 75.3%), in patients younger than 18 years (21.2% vs 24.7%), respectively. For soft tissue sarcoma stages I-II, III, (unresectable)/IV 1.0, 17.5 and 81.5% trials, respectively, have been held in Western Europe, 0, 18.2 and 81.8% trials in Eastern Europe. The most frequent clinical trials studies of targeted therapy, chemotherapy and combination treatment, constituting 35.9%, 20.4% and 17.2% trials in Western Europe and in 18.2%, 27.3% and 16.7% trials in Eastern Europe, respectively. Only 14.1% of trials are currently recruiting patients in Eastern Europe while 85.9% of recruitment is in Western Europe.

Conclusions

Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe is quite different. Participation in clinical trials could help as patients from countries with low access to innovative medicines or oncologists could get necessary experience.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.